Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomized, Double Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo

NCT04487860 is registered in ClinicalTrials.gov with Ache Laboratorios Farmaceuticos S.A. as lead sponsor.

NCT NCT04487860
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04487860 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomized, Double Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo
Lead sponsor
Ache Laboratorios Farmaceuticos S.A.
Phase
Phase 2
Overall status
Completed
Start date
January 13, 2021
Completion date
February 27, 2023
Enrollment
327 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

non-segmental vitiligo